Klont Frank, Horvatovich Peter, Govorukhina Natalia, Bischoff Rainer
Department of Analytical Biochemistry, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
Methods Mol Biol. 2019;1959:1-22. doi: 10.1007/978-1-4939-9164-8_1.
The translation of promising biomarkers, which were identified in biomarker discovery experiments, to clinical assays is one of the key challenges in present-day proteomics research. Many so-called "biomarker candidates" fail to progress beyond the discovery phase, and much emphasis is placed on pre- and post-analytical variability in an attempt to provide explanations for this bottleneck in the biomarker development pipeline. With respect to such variability, there is a large number of pre- and post-analytical factors which may impact the outcomes of proteomics experiments and thus necessitate tight control. This chapter highlights some of these factors and provides guidance for addressing them on the basis of examples from previously published proteomics studies.
在生物标志物发现实验中鉴定出的有前景的生物标志物向临床检测方法的转化，是当今蛋白质组学研究的关键挑战之一。许多所谓的“生物标志物候选物”未能超越发现阶段，并且人们非常强调分析前和分析后的变异性，试图为生物标志物开发流程中的这一瓶颈提供解释。关于这种变异性，有大量分析前和分析后的因素可能会影响蛋白质组学实验的结果，因此需要严格控制。本章重点介绍其中一些因素，并根据先前发表的蛋白质组学研究实例为解决这些因素提供指导。
